Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorAbd-Rahman, A.en_US
dc.contributorZaloumis, S.en_US
dc.contributorMcCarthy, J.en_US
dc.contributorSimpson, J.en_US
dc.contributorCommons, Robert J.en_US
dc.description.abstractThe emergence and spread of parasite resistance to currently available antimalarials has highlighted the importance of developing novel antimalarials. This scoping review provides an overview of antimalarial drug candidates undergoing phase I and II studies between 1 January 2016 and 28 April 2021. PubMed, Web of Science, Embase, clinical trial registries, and reference lists were searched for relevant studies. Information regarding antimalarial compound details, clinical trial characteristics, study population, and drug pharmacokinetics and pharmacodynamics (PK-PD) were extracted. A total of 50 studies were included, of which 24 had published their results and 26 were unpublished. New antimalarial compounds were evaluated as monotherapy (28 studies, 14 drug candidates) and combination therapy (9 studies, 10 candidates). Fourteen active compounds were identified in the current antimalarial drug development pipeline together with 11 compounds that are inactive, 6 due to insufficient efficacy. PK-PD data were available from 24 studies published as open-access articles. Four unpublished studies have made their results publicly available on clinical trial registries. The terminal elimination half-life of new antimalarial compounds ranged from 14.7 to 483 h. The log10 parasite reduction ratio over 48 h and parasite clearance half-life for Plasmodium falciparum following a single-dose monotherapy were 1.55 to 4.1 and 3.4 to 9.4 h, respectively. The antimalarial drug development landscape has seen a number of novel compounds, with promising PK-PD properties, evaluated in phase I and II studies over the past 5 years. Timely public disclosure of PK-PD data is crucial for informative decision-making and drug development strategy.en_US
dc.description.provenanceSubmitted by Gemma Siemensma ( on 2022-05-06T02:01:43Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma ( on 2022-06-01T06:50:43Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2022-06-01T06:50:43Z (GMT). No. of bitstreams: 0 Previous issue date: 2022en
dc.titleScoping review of antimalarial drug candidates in phase I and II drug development.en_US
dc.typeJournal Articleen_US
dc.bibliographicCitation.titleAntimicrobial Agents and Chemotherapyen_US
dc.subject.healththesaurusDRUG DEVELOPMENTen_US
dc.subject.healththesaurusPHASE Ien_US
dc.subject.healththesaurusPHASE 2en_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.